Business · 04/08/2023Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for VERCISE DEEP BRAIN STIMULATION SYSTEM
Summary
The U.S. Food and Drug Administration (FDA) has set a regulatory review period for VERCISE DEEP BRAIN STIMULATION SYSTEM, a medical device, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →